Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Weighted Average) (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $97.5 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 21.69% year-over-year to $97.5 million; the TTM value through Mar 2026 reached $97.5 million, up 21.69%, while the annual FY2025 figure was $84.5 million, 12.59% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $97.5 million in Q1 2026 for Kymera Therapeutics, up from $84.5 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $97.5 million in Q1 2026 and bottomed at $51.7 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $68.3 million, with a median of $70.8 million recorded in 2024.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 7.13% in 2023 and then rose 28.58% in 2024.
  • Kymera Therapeutics' Shares Outstanding (Weighted Average) stood at $53.9 million in 2022, then grew by 8.22% to $58.4 million in 2023, then grew by 28.58% to $75.0 million in 2024, then increased by 12.59% to $84.5 million in 2025, then increased by 15.44% to $97.5 million in 2026.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $97.5 million, $84.5 million, and $82.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.